In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells
- PMID: 19908943
- DOI: 10.3109/15476910903236134
In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells
Abstract
Multiple myeloma has been considered a weakly immunogenic malignancy that can cause profound defects in the immune system. An important issue for the immunotherapy of myeloma is the identification of appropriate tumor-associated antigens (TAAs). Recently, hTERT (human telomerase reverse transcriptase) was detected on a majority of human malignancies. In the studies reported here, we studied antigen-specific and HLA-A2-restricted cytotoxic activity against an ARH77 myeloma cell line in vitro. An HLA-A2-specific hTERT-derived nonapeptide ((540)ILAKFLHWL(548)) was used as a TAA. Myeloma-specific cytotoxic activity of hTERT-reactive cytotoxic lymphocytes (CTLs) was established by repeated stimulation of the CTLs via dendritic cells loaded with hTERT-derived nonapeptide. These studies were able to demonstrate that hTERT-reactive T-lymphocytes can be identified and expanded using relatively simple in vitro techniques consisting of antigen-specific stimulation, immunomagnetic sorting, and then induction of rapid expansion.
Similar articles
-
Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.Cancer Res. 2005 Jun 15;65(12):5417-27. doi: 10.1158/0008-5472.CAN-04-2991. Cancer Res. 2005. PMID: 15958591
-
[The preparation of myeloma-specific T cells activated with dendritic cells loaded with nonapeptides derived from mucin protein MUC1 and catalytic subunit of telomerase hTERT].Klin Onkol. 2008;21(2):59-65. Klin Onkol. 2008. PMID: 19102213 Czech.
-
Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.Exp Hematol. 2007 Feb;35(2):297-304. doi: 10.1016/j.exphem.2006.10.006. Exp Hematol. 2007. PMID: 17258078
-
The immunogenicity of the hTERT540-548 peptide in cancer.Clin Cancer Res. 2008 Jan 1;14(1):4-7. doi: 10.1158/1078-0432.CCR-07-4590. Clin Cancer Res. 2008. PMID: 18172245 Review.
-
Can hTERT peptide (540-548) -specific CD8 T cells recognize and kill tumor cells?Cancer Immun. 2002 Oct 14;2:14. Cancer Immun. 2002. PMID: 12747759 Review.
Cited by
-
Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.Clin Dev Immunol. 2012;2012:753407. doi: 10.1155/2012/753407. Epub 2012 May 10. Clin Dev Immunol. 2012. PMID: 22649466 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials